Published in CMAJ on March 23, 1999
Association of postoperative complications with hospital costs and length of stay in a tertiary care center. J Gen Intern Med (2006) 1.42
Outcomes and costs of coronary artery bypass grafting: comparison between octogenarians and septuagenarians at a tertiary care centre. CMAJ (2001) 1.33
Vitamin B12 injections versus oral supplements. How much money could be saved by switching from injections to pills? Can Fam Physician (2001) 1.22
Coronary artery bypass grafting in elderly patients: the price of success. CMAJ (1999) 0.84
Considering the cost of CABG. CMAJ (1999) 0.75
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet (1994) 11.37
The distinction between cost and charges. Ann Intern Med (1982) 5.93
Hazards of hospitalization of the elderly. Ann Intern Med (1993) 4.75
A predictive index for functional decline in hospitalized elderly medical patients. J Gen Intern Med (1993) 2.34
Use of coronary artery bypass surgery in the United States and Canada. Influence of age and income. JAMA (1993) 2.17
Coronary artery bypass surgery in Canada. Health Rep (1990) 1.95
The natural history of functional morbidity in hospitalized older patients. J Am Geriatr Soc (1990) 1.90
Monitoring the diffusion of a technology: coronary artery bypass surgery in Ontario. Am J Public Health (1988) 1.86
Coronary artery bypass grafting in Canada: What is its rate of use? Which rate is right? CMAJ (1992) 1.71
Stroke following coronary artery bypass grafting: a ten-year study. Ann Thorac Surg (1985) 1.68
Changes in mortality after myocardial revascularization in the elderly. The national Medicare experience. Ann Intern Med (1994) 1.49
Determinants of prolonged length of hospital stay after coronary bypass surgery. Circulation (1989) 1.39
Trends in the age and sex of patients undergoing coronary revascularisation in the United Kingdom 1987-93. Br Heart J (1994) 1.37
Physiology and complications of bed rest. J Am Geriatr Soc (1988) 1.32
Predictors of cognitive decline after cardiac operation. Ann Thorac Surg (1995) 1.28
Determinants of hospital charges for coronary artery bypass surgery: the economic consequences of postoperative complications. Am J Cardiol (1990) 1.24
Trends in coronary artery bypass grafting in Ontario from 1981 to 1989. CMAJ (1993) 1.20
Differential effects of advanced age on neurologic and cardiac risks of coronary artery operations. J Thorac Cardiovasc Surg (1992) 1.18
Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. J Clin Epidemiol (1993) 1.14
Hospital care for elderly patients with diseases of the circulatory system. A comparison of hospital use in the United States and Canada. N Engl J Med (1989) 1.10
Hospital-associated deconditioning and dysfunction. J Am Geriatr Soc (1991) 1.08
The changing profile of the patient undergoing coronary artery bypass surgery. J Am Coll Cardiol (1988) 1.05
Coronary artery bypass grafting: how much does it cost? CMAJ (1992) 0.98
Comparative costs versus symptomatic and employment benefits of medical and surgical treatment of stable angina pectoris. Med Care (1985) 0.98
Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol (1993) 0.97
Effect of advancing age on cost and outcome of coronary artery bypass grafting. Ann Thorac Surg (1994) 0.96
Changes in patient characteristics and surgical outcomes for coronary artery bypass surgery 1972-82. Am J Public Health (1987) 0.96
Rehospitalizations after coronary revascularization among Medicare beneficiaries. Am J Cardiol (1993) 0.93
Mortality, morbidity, and cost-accounting related to coronary artery bypass graft surgery in the elderly. Ann Thorac Surg (1985) 0.90
Coronary bypass surgery: is the operation different today? J Thorac Cardiovasc Surg (1991) 0.90
Cost of coronary artery bypass surgery: a pilot study. Can J Surg (1985) 0.89
Cost-effectiveness and predictors of early extubation. Ann Thorac Surg (1995) 0.88
Coronary artery bypass grafting in Alberta from 1984 to 1989. Can J Cardiol (1993) 0.88
Changes in patients undergoing coronary artery bypass grafting: 1987-1990. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg (1994) 0.88
Acute hospital care of the elderly: minimizing the risk of functional decline. Cleve Clin J Med (1995) 0.87
A flow cytometric study of the membrane potential of natural killer and K562 cells during the cytotoxic process. J Immunol Methods (1993) 0.87
Comparative costs of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting in multivessel coronary artery disease. Am J Cardiol (1988) 0.86
Predicting the occurrence of adverse events after coronary artery bypass surgery. Ann Intern Med (1993) 0.86
Stroke in coronary artery bypass graft surgery: an analysis of the CASS experience. The participants in the Coronary Artery Surgery Study. Int J Cardiol (1992) 0.86
Cardiac operations in patients aged 70 years and over: mortality, length of stay, and hospital charge. Ann Thorac Surg (1995) 0.86
Risk factors for stroke following coronary bypass surgery. J Card Surg (1995) 0.86
The cost-effectiveness of routine post myocardial infarction exercise stress testing. Can J Cardiol (1990) 0.85
Risk factors for stroke after coronary artery bypass. J Thorac Cardiovasc Surg (1992) 0.83
Use it or lose it--the hazards of bed rest and inactivity. West J Med (1991) 0.81
Coronary artery bypass grafting in the elderly: changing trends and results. J Cardiovasc Surg (Torino) (1992) 0.80
The indomitable spirit. Am J Public Health (1988) 0.77
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med (1998) 11.14
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ (1992) 10.40
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 9.81
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell (1995) 9.22
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
Screening for prostate cancer. A decision analytic view. JAMA (1994) 5.83
Meta-analysis in clinical research. Ann Intern Med (1987) 5.16
Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol (1992) 4.86
Shopping around for hospital services: a comparison of the United States and Canada. JAMA (1998) 4.41
What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr (1987) 4.21
Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell (2000) 4.19
Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem (1996) 3.97
On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics (2001) 3.83
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science (1997) 3.51
Screening for colon cancer--can we afford colonoscopy? N Engl J Med (2001) 3.48
A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem (1994) 3.13
Direct and indirect costs of asthma in Canada, 1990. CMAJ (1996) 3.07
Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology (1989) 2.88
Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (1996) 2.87
Role of CED-4 in the activation of CED-3. Nature (1997) 2.76
Nutritional assessment: a comparison of clinical judgement and objective measurements. N Engl J Med (1982) 2.74
Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis (1999) 2.69
Comparison of an aggressive (U.S.) and a less aggressive (Canadian) policy for cholesterol screening and treatment. Ann Intern Med (1991) 2.61
Primer on medical decision analysis: Part 1--Getting started. Med Decis Making (1997) 2.61
Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA (2001) 2.49
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem (1998) 2.25
Randomized, controlled trial of an interactive videodisc decision aid for patients with ischemic heart disease. J Gen Intern Med (2000) 2.21
Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol (1999) 2.19
Nonionic contrast media: economic analysis and health policy development. CMAJ (1989) 2.13
Predicting cardiac complications in patients undergoing non-cardiac surgery. J Gen Intern Med (1986) 2.13
When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med (1985) 2.11
A randomized crossover trial of Quick Medical Reference (QMR) as a teaching tool for medical interns. J Gen Intern Med (1994) 2.10
A role for FADD in T cell activation and development. Immunity (1998) 2.09
Cardiac assessment for patients undergoing noncardiac surgery. A multifactorial clinical risk index. Arch Intern Med (1986) 2.08
Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med (1995) 2.07
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Cost and health implications of cholesterol lowering. Circulation (1992) 2.00
Proteolytic activation of the cell death protease Yama/CPP32 by granzyme B. Proc Natl Acad Sci U S A (1996) 1.90
Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology (1995) 1.90
Primer on medical decision analysis: Part 3--Estimating probabilities and utilities. Med Decis Making (1997) 1.84
Prognosis, survival, and the expenditure of hospital resources for patients in an intensive-care unit. N Engl J Med (1981) 1.72
Age distribution of Helicobacter pylori seroprevalence among young children in a United States/Mexico border community: evidence for transitory infection. Am J Epidemiol (1999) 1.68
Perioperative parenteral nutrition: a meta-analysis. Ann Intern Med (1987) 1.62
Primer on medical decision analysis: Part 2--Building a tree. Med Decis Making (1997) 1.58
Molecular ordering of apoptotic mammalian CED-3/ICE-like proteases. J Biol Chem (1996) 1.57
Primer on medical decision analysis: Part 4--Analyzing the model and interpreting the results. Med Decis Making (1997) 1.57
Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med (1997) 1.53
Tentative guidelines for using clinical and economic evaluations revisited. CMAJ (1993) 1.53
Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decis Making (2000) 1.51
The relation of conjunctival pallor to the presence of anemia. J Gen Intern Med (1997) 1.50
Clinical and population epidemiology: beyond sibling rivalry? J Clin Epidemiol (1990) 1.49
Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet (1996) 1.49
Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. JPEN J Parenter Enteral Nutr (1984) 1.46
Cost induced by hip fractures. Ir Med J (2008) 1.46
Preoperative fasting for preventing perioperative complications in children. Cochrane Database Syst Rev (2005) 1.45
Autoimmune encephalopathy presenting as a 'posterior circulation stroke'. J Neurol (2010) 1.45
OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology (2010) 1.45
Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus. J Mol Biol (2000) 1.44
Should ERCP be routine after an episode of "idiopathic" pancreatitis? A cost-utility analysis. Gastrointest Endosc (1996) 1.41
Improving prevention in primary care: evaluating the effectiveness of outreach facilitation. Fam Pract (2008) 1.40
Universal hepatitis B vaccination: the economics of prevention. CMAJ (1992) 1.40
Primer on medical decision analysis: Part 5--Working with Markov processes. Med Decis Making (1997) 1.39
The effectiveness of a regulatory strategy in containing hospital costs. The Ontario experience, 1967-1981. N Engl J Med (1983) 1.39
Management of asymptomatic chronic aortic regurgitation with left ventricular dysfunction: a decision analysis. J Gen Intern Med (1990) 1.39
Regional variation in medical care. N Engl J Med (1995) 1.35
Thrombospondin-induced adhesion of human keratinocytes. J Clin Invest (1988) 1.33
Predicting nutrition-associated complications for patients undergoing gastrointestinal surgery. JPEN J Parenter Enteral Nutr (1987) 1.32
Residential mobility and risk of childhood acute lymphoblastic leukaemia: an ecological study. Br J Cancer (2007) 1.30
Characterization of mouse thrombospondin 2 sequence and expression during cell growth and development. J Biol Chem (1992) 1.27
When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings? CMAJ (1987) 1.25
A mass media programme to prevent smoking among adolescents: costs and cost effectiveness. Tob Control (1997) 1.24
Epidemic of the acquired immunodeficiency syndrome: a need for economic and social planning. Ann Intern Med (1983) 1.24
Preoperative cardiac risk assessment for patients having peripheral vascular surgery. Ann Intern Med (1992) 1.23
Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med (1996) 1.22
Cost-effectiveness analysis of potential improvements to emergency medical services for victims of out-of-hospital cardiac arrest. Ann Emerg Med (1996) 1.21
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol (1998) 1.17
A second, expressed thrombospondin gene (Thbs2) exists in the mouse genome. J Biol Chem (1991) 1.15
Effectiveness of emergency medical services for victims of out-of-hospital cardiac arrest: a metaanalysis. Ann Emerg Med (1996) 1.15
Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int (2012) 1.14
Synthesis of wild type and mutant human hemoglobins in Saccharomyces cerevisiae. Biotechnology (N Y) (1991) 1.14
A clinician's guide to utility measurement. Prim Care (1995) 1.13